secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K/A
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001140361-26-010656
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant subsidiary Genevant settles LNP patent litigation with Moderna; includes license and payments
--------------------------------------------------------------------------------

- Settlement resolves all US and international patent infringement litigation between Genevant/Arbutus and Moderna over LNP technology in COVID-19 and other mRNA vaccines.
- Moderna receives broad license to Genevant/Arbutus patent rights for defined Moderna Licensed Products, including SPIKEVAX, mNEXSPIKE, mRESVIA, and certain other mRNA vaccines.
- Moderna will make a noncontingent lump-sum payment (amount redacted) and a contingent payment tied to the outcome of Moderna's appeal on the §1498 government-contractor defense.
- Parties stipulate to dismissal of US and ex-US litigation with prejudice; Moderna retains right to appeal only on the §1498 Disputed Matter.
- Moderna agrees not to challenge validity/enforceability of specified patents owned by Genevant/Arbutus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/ef20068452_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-010656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer